---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-216743"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2026-05-11T20:05:34+00:00"
generated_at: "2026-05-11T22:49:04.504915+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aura Q1 net loss $33.7M; Phase 3 CoMpass enrollment mid-2026; new CEO appointed

## Summary
- Net loss of $33.7M in Q1 2026; R&D expenses $28.0M (up from $23.3M) reflecting Phase 3 costs.
- Phase 3 CoMpass trial in early choroidal melanoma enrollment expected to complete mid-2026; topline data in 2H 2027.
- Natalie Holles appointed CEO and President effective April 30, 2026, succeeding founder Elisabet de los Pinos.
- Completed $299M equity offering (net ~$280.8M); used $39M to repurchase shares from Matrix Capital; cash into 2H 2028.
- Pipeline: Phase 2 choroidal metastases data in 2026; Phase 1 ocular cancer PoC data in 2026; bladder cancer data mid-2026.

## SEC filing metadata
- accession: 0001193125-26-216743
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2026-05-11T20:05:34+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312526216743/0001193125-26-216743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312526216743/aura-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-216743
- JSON: https://secwatch.observer/filing/0001193125-26-216743.json
- Plain text: https://secwatch.observer/filing/0001193125-26-216743.txt

## Key facts
- Earnings Releases
  Aura Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income $33.7 million.
  - Period: the first quarter ended March 31, 2026
  - Net income: $33.7 million
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2026, was $33.7 million, compared to $27.5 million for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000119312526216743/0001193125-26-216743-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.